Machiavelli M, Leone B, Romero A, Perez J, Vallejo C, Bianco A, Rodriguez R, Estevez R, Chacon R, Dansky C
Grupo Oncologico Cooperativo del Sur (GOCS), Hospital Municipal Leonidas Lucero, Bahia Blanca, Argentina.
Oncology. 1989;46(2):78-82. doi: 10.1159/000226689.
To evaluate the influence of delay between first symptom and first treatment upon survival the medical records of 596 patients with breast cancer were reviewed. The following intervals were considered: less than 3 months; 3-6 months and greater than 6 months. Patients in the less than 3 months delay group had a better distribution by clinical stages and a 10-year survival rate higher than those in the longer delay groups (p = 0.034). However, within each stage no statistically significant difference in survival according to delay was observed. A Cox multivariate analysis revealed that performance status and stage of disease were independent predictors of survival, but not delay. Assuming the best prognosis for patients with clinical stages I and II and less than 3 months delay, the group with longer delay times had 15 deaths over what would have been predicted. This adverse effect was observed almost exclusively among patients over age 50 (14/15).
为评估首次出现症状至首次治疗之间的延迟对生存率的影响，我们回顾了596例乳腺癌患者的病历。考虑了以下时间段：少于3个月；3至6个月；大于6个月。延迟少于3个月组的患者在临床分期上分布更佳，其10年生存率高于延迟时间更长的组（p = 0.034）。然而，在每个分期内，未观察到根据延迟时间在生存率上有统计学显著差异。Cox多因素分析显示，功能状态和疾病分期是生存的独立预测因素，但延迟时间不是。假设临床I期和II期且延迟少于3个月的患者预后最佳，延迟时间较长的组比预测的多死亡15例。这种不良影响几乎仅在50岁以上的患者中观察到（14/15）。
